基于网络药理学、分子对接和实验验证探索柴胡当归汤治疗乳腺癌的潜力。

IF 3.4 4区 医学 Q2 ONCOLOGY
Breast Cancer : Targets and Therapy Pub Date : 2025-05-10 eCollection Date: 2025-01-01 DOI:10.2147/BCTT.S510274
Yusheng Liu, Junfeng Zhang, Yigui Lai, Chunying Wu, Dongsheng Liu, Rongyao Liang, Gang Chen, Xuefeng Jiang
{"title":"基于网络药理学、分子对接和实验验证探索柴胡当归汤治疗乳腺癌的潜力。","authors":"Yusheng Liu, Junfeng Zhang, Yigui Lai, Chunying Wu, Dongsheng Liu, Rongyao Liang, Gang Chen, Xuefeng Jiang","doi":"10.2147/BCTT.S510274","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chaihu-Danggui Tang (CHDGT) has a long history in traditional Chinese medicine (TCM) as an adjuvant therapy for breast cancer (BC), but its precise anti-tumor mechanisms remain unknown. In this study, we used network pharmacology, molecular docking, and experimental validation methods to investigate the core components, key targets, and possible mechanisms through which CHDGT may exert therapeutic effects in BC treatment.</p><p><strong>Methods: </strong>The Traditional Chinese Medicine Systems Pharmacology (TCMSP) was employed to obtain the active ingredient and targets of CHDGT. Meanwhile, the GeneCards databases were used to retrieve pertinent targets for BC. The Venn plot was used to obtain intersection targets. Cytoscape software was used to construct an \"CHDGT-active ingredients-targets\" network and identify core targets. The common targets after STRING processing were imported into the Metascape database for GO and KEGG pathway enrichment analysis. Molecular docking of key ingredients and core targets of drugs was accomplished using Autodock and PyMol software. The cell and animal experiments confirmed CHDGT efficacy and mechanism in treating BC.</p><p><strong>Results: </strong>We screened 5 key effector components, 8 core targets, and multiple signaling pathways of CHDGT in treating BC. In vitro, the results of CCK-8 assay showed that CHDGT can dose-dependently inhibits BC cell growth, and at 100 mg L<sup>-1</sup> after 48 hours, the cell inhibition rate reached approximately 50%. Further analysis showed that CHDGT can promote apoptosis of BC cell, and regulate the expression levels of apoptosis-related genes, such as Caspase3, p53, and Bcl-2. The animal experiments verified that CHDGT can significantly inhibit the progression of BC, the tumor inhibition rate of CHDGT-H groups was as high as 60.06 ± 4.82%. In addition, H&E staining and blood biochemical analysis suggest that CHDGT exhibits favorable safety.</p><p><strong>Conclusion: </strong>This study may provide perspectives for the development of anticancer Chinese herbs for the treatment of BC.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"385-401"},"PeriodicalIF":3.4000,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077417/pdf/","citationCount":"0","resultStr":"{\"title\":\"Exploring the Potential of Chaihu-Danggui Tang in Breast Cancer Treatment Based on Network Pharmacology, Molecular Docking, and Experimental Validation.\",\"authors\":\"Yusheng Liu, Junfeng Zhang, Yigui Lai, Chunying Wu, Dongsheng Liu, Rongyao Liang, Gang Chen, Xuefeng Jiang\",\"doi\":\"10.2147/BCTT.S510274\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Chaihu-Danggui Tang (CHDGT) has a long history in traditional Chinese medicine (TCM) as an adjuvant therapy for breast cancer (BC), but its precise anti-tumor mechanisms remain unknown. In this study, we used network pharmacology, molecular docking, and experimental validation methods to investigate the core components, key targets, and possible mechanisms through which CHDGT may exert therapeutic effects in BC treatment.</p><p><strong>Methods: </strong>The Traditional Chinese Medicine Systems Pharmacology (TCMSP) was employed to obtain the active ingredient and targets of CHDGT. Meanwhile, the GeneCards databases were used to retrieve pertinent targets for BC. The Venn plot was used to obtain intersection targets. Cytoscape software was used to construct an \\\"CHDGT-active ingredients-targets\\\" network and identify core targets. The common targets after STRING processing were imported into the Metascape database for GO and KEGG pathway enrichment analysis. Molecular docking of key ingredients and core targets of drugs was accomplished using Autodock and PyMol software. The cell and animal experiments confirmed CHDGT efficacy and mechanism in treating BC.</p><p><strong>Results: </strong>We screened 5 key effector components, 8 core targets, and multiple signaling pathways of CHDGT in treating BC. In vitro, the results of CCK-8 assay showed that CHDGT can dose-dependently inhibits BC cell growth, and at 100 mg L<sup>-1</sup> after 48 hours, the cell inhibition rate reached approximately 50%. Further analysis showed that CHDGT can promote apoptosis of BC cell, and regulate the expression levels of apoptosis-related genes, such as Caspase3, p53, and Bcl-2. The animal experiments verified that CHDGT can significantly inhibit the progression of BC, the tumor inhibition rate of CHDGT-H groups was as high as 60.06 ± 4.82%. In addition, H&E staining and blood biochemical analysis suggest that CHDGT exhibits favorable safety.</p><p><strong>Conclusion: </strong>This study may provide perspectives for the development of anticancer Chinese herbs for the treatment of BC.</p>\",\"PeriodicalId\":9106,\"journal\":{\"name\":\"Breast Cancer : Targets and Therapy\",\"volume\":\"17 \",\"pages\":\"385-401\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-05-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077417/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer : Targets and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/BCTT.S510274\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/BCTT.S510274","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:柴胡当归汤作为乳腺癌的辅助治疗中药已有很长的历史,但其确切的抗肿瘤机制尚不清楚。本研究采用网络药理学、分子对接、实验验证等方法,探讨CHDGT在BC治疗中发挥作用的核心成分、关键靶点及可能机制。方法:采用中药系统药理学(TCMSP)方法获得CHDGT的有效成分和靶点。同时,利用GeneCards数据库检索BC的相关靶点。使用维恩图获得相交目标。利用Cytoscape软件构建“chdgt -活性成分-靶点”网络,识别核心靶点。将STRING处理后的常见靶点导入metscape数据库,进行GO和KEGG通路富集分析。利用Autodock和PyMol软件完成药物关键成分与核心靶点的分子对接。细胞和动物实验证实了CHDGT治疗BC的有效性和机制。结果:我们筛选了CHDGT治疗BC的5个关键效应组分、8个核心靶点和多种信号通路。体外CCK-8实验结果显示,CHDGT能剂量依赖性地抑制BC细胞生长,在100 mg L-1作用48小时后,细胞抑制率可达50%左右。进一步分析发现CHDGT可促进BC细胞凋亡,并可调节凋亡相关基因Caspase3、p53、Bcl-2的表达水平。动物实验证实,CHDGT能显著抑制BC的进展,CHDGT- h组的肿瘤抑制率高达60.06±4.82%。此外,H&E染色和血液生化分析表明CHDGT具有良好的安全性。结论:本研究为开发抗癌中药治疗BC提供了新的思路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Exploring the Potential of Chaihu-Danggui Tang in Breast Cancer Treatment Based on Network Pharmacology, Molecular Docking, and Experimental Validation.

Background: Chaihu-Danggui Tang (CHDGT) has a long history in traditional Chinese medicine (TCM) as an adjuvant therapy for breast cancer (BC), but its precise anti-tumor mechanisms remain unknown. In this study, we used network pharmacology, molecular docking, and experimental validation methods to investigate the core components, key targets, and possible mechanisms through which CHDGT may exert therapeutic effects in BC treatment.

Methods: The Traditional Chinese Medicine Systems Pharmacology (TCMSP) was employed to obtain the active ingredient and targets of CHDGT. Meanwhile, the GeneCards databases were used to retrieve pertinent targets for BC. The Venn plot was used to obtain intersection targets. Cytoscape software was used to construct an "CHDGT-active ingredients-targets" network and identify core targets. The common targets after STRING processing were imported into the Metascape database for GO and KEGG pathway enrichment analysis. Molecular docking of key ingredients and core targets of drugs was accomplished using Autodock and PyMol software. The cell and animal experiments confirmed CHDGT efficacy and mechanism in treating BC.

Results: We screened 5 key effector components, 8 core targets, and multiple signaling pathways of CHDGT in treating BC. In vitro, the results of CCK-8 assay showed that CHDGT can dose-dependently inhibits BC cell growth, and at 100 mg L-1 after 48 hours, the cell inhibition rate reached approximately 50%. Further analysis showed that CHDGT can promote apoptosis of BC cell, and regulate the expression levels of apoptosis-related genes, such as Caspase3, p53, and Bcl-2. The animal experiments verified that CHDGT can significantly inhibit the progression of BC, the tumor inhibition rate of CHDGT-H groups was as high as 60.06 ± 4.82%. In addition, H&E staining and blood biochemical analysis suggest that CHDGT exhibits favorable safety.

Conclusion: This study may provide perspectives for the development of anticancer Chinese herbs for the treatment of BC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
40
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信